Immunogenicity, transplacental transfer of pertussis antibodies and safety following pertussis immunization during pregnancy: Evidence from a randomized, placebo-controlled trial.

•A 3-component Tdap vaccine was administered during the third trimester of pregnancy.•This resulted in high levels of pertussis antibodies in newborns’ cord blood.•The Tdap vaccine had a clinically acceptable safety profile in mothers and their fetuses/newborns.•These data support routine maternal Tdap vaccination to prevent newborn pertussis disease.